Compare Cadila Healthcare with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs NOVARTIS - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE NOVARTIS CADILA HEALTHCARE/
NOVARTIS
 
P/E (TTM) x 14.5 487.1 3.0% View Chart
P/BV x 2.8 28.3 10.0% View Chart
Dividend Yield % 1.4 1.6 89.5%  

Financials

 CADILA HEALTHCARE   NOVARTIS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
NOVARTIS
Mar-18
CADILA HEALTHCARE/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs558758 73.6%   
Low Rs362579 62.4%   
Sales per share (Unadj.) Rs116.3228.4 50.9%  
Earnings per share (Unadj.) Rs17.931.7 56.3%  
Cash flow per share (Unadj.) Rs23.132.8 70.6%  
Dividends per share (Unadj.) Rs3.5010.00 35.0%  
Dividend yield (eoy) %0.81.5 50.9%  
Book value per share (Unadj.) Rs85.4297.1 28.7%  
Shares outstanding (eoy) m1,023.7424.69 4,146.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.9 135.1%   
Avg P/E ratio x25.721.1 122.2%  
P/CF ratio (eoy) x19.920.4 97.4%  
Price / Book Value ratio x5.42.2 239.2%  
Dividend payout %19.631.5 62.2%   
Avg Mkt Cap Rs m470,66416,505 2,851.6%   
No. of employees `00011.80.7 1,769.3%   
Total wages/salary Rs m18,5451,445 1,283.1%   
Avg. sales/employee Rs Th10,072.78,441.3 119.3%   
Avg. wages/employee Rs Th1,569.12,163.6 72.5%   
Avg. net profit/employee Rs Th1,547.71,173.1 131.9%   
INCOME DATA
Net Sales Rs m119,0495,639 2,111.2%  
Other income Rs m1,1321,718 65.9%   
Total revenues Rs m120,1817,357 1,633.5%   
Gross profit Rs m28,475-63 -45,560.0%  
Depreciation Rs m5,38825 21,296.4%   
Interest Rs m91155 1,647.4%   
Profit before tax Rs m23,3081,575 1,479.7%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644792 713.0%   
Profit after tax Rs m18,292784 2,334.4%  
Gross profit margin %23.9-1.1 -2,158.0%  
Effective tax rate %24.250.3 48.2%   
Net profit margin %15.413.9 110.6%  
BALANCE SHEET DATA
Current assets Rs m82,0059,522 861.3%   
Current liabilities Rs m60,7203,296 1,842.2%   
Net working cap to sales %17.9110.4 16.2%  
Current ratio x1.42.9 46.8%  
Inventory Days Days7337 199.8%  
Debtors Days Days9828 345.9%  
Net fixed assets Rs m83,70346 181,963.0%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m86,4217,213 1,198.1%   
Net worth Rs m87,4457,336 1,191.9%   
Long term debt Rs m25,5510-   
Total assets Rs m180,65311,105 1,626.7%  
Interest coverage x26.629.5 90.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.5 129.8%   
Return on assets %10.67.6 140.7%  
Return on equity %20.910.7 195.8%  
Return on capital %22.022.2 98.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68361 70,434.0%   
Fx outflow Rs m11,2423,630 309.7%   
Net fx Rs m31,441-3,570 -880.8%   
CASH FLOW
From Operations Rs m9,1931,610 571.0%  
From Investments Rs m-9,737687 -1,417.3%  
From Financial Activity Rs m515-2,677 -19.2%  
Net Cashflow Rs m-29-380 7.6%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 2.0 415.0%  
FIIs % 5.9 1.6 368.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.5 51.2%  
Shareholders   44,069 41,647 105.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 13, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - PLETHICO PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS